{
  "abstract": "Type 2 conventional dendritic cell (cDC2) gene signature was shown to be associated with better overall survival in patients with lung cancer and a fraction of patients with breast carcinoma, indicating that they may possess antitumoral function. Nevertheless, unraveling the antitumoral role of cDC2s proved to be challenging due to their complex development and heterogeneity. Here, we discuss findings showcasing the ability of cDC2s to prime cytotoxic CD8+ T cells upon acquiring a distinct activation state, leading to effective immune responses against viral infections and cancer. This cDC2 activation state is induced by type I interferon (IFN) and consequently shows enrichment in IFN-stimulated genes.",
  "authors": [
    {
      "affiliations": [
        "Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium",
        "Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium"
      ],
      "name": "Ahmed E I Hamouda"
    },
    {
      "affiliations": [
        "Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium",
        "Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium"
      ],
      "name": "Damya Laoui"
    }
  ],
  "title": "Role of cDC2 in priming CD8+ T cells in cancer",
  "uid": "8ca248ab-20b9-5fd7-b7cb-b2d03e30647c"
}